lilly glp 1 pill says its experimental GLP-1 better than Novo's Rybelsus in diabetes study FDA grants speedy approval to

thaliana (Li et al., 2004)

Appl Biochem Biotechnol 168:198205

What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale

Nearly all PCOS patients prescribed semaglutide or tirzepatide also had obesity or type 2 diabetes, suggesting use remains primarily tied to metabolic indications, though broader interest in PCOS benefits is growing within scientific literature

Tirzepatide does not directly burn fat like a stimulant

Subscribe for more Diabetes Awareness Month videos this